Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.58 |
| ▸ | GSK3B | P49841 | 6/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684561 | 0.85 | GSK3B (0.55) | CYP4F2CYP4A11GSK3BPTPN1FOLH1 | |
| SCHEMBL5052377 | 0.84 | GSK3B (0.50) | CYP4F2CYP4A11GSK3BPTPN1 | |
| SCHEMBL27588759 | 0.81 | GSK3B (0.55) | GSK3BPTPN1FOLH1 | |
| SCHEMBL7860030 | 0.81 | CYP4F2 (0.49) | CYP4F2CYP4A11GSK3BPTPN1 | |
| SCHEMBL9409741 | 0.80 | GSK3B (0.70) | GSK3BPTPN1TDP1 | |
| SCHEMBL11827400 | 0.80 | LPL (0.50) | CYP4F2CYP4A11GSK3BPTPN1 | |
| SCHEMBL14403821 | 0.80 | GSK3B (0.53) | GSK3BPTPN1FOLH1 | |
| SCHEMBL30988817 | 0.80 | GSK3B (0.53) | CYP4F2CYP4A11GSK3BPTPN1FOLH1 | |
| SCHEMBL27280115 | 0.80 | LOXL2 (0.57) | GSK3BPTPN1FOLH1 | |
| SCHEMBL4344951 | 0.80 | GSK3B (0.53) | CYP4F2CYP4A11GSK3BPTPN1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | CYP4F2 3741/4885CYP4A11 2667/4885GSK3B 3790/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | CYP4F2 3413/4885CYP4A11 3227/4885GSK3B 3806/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | CYP4F2 2773/4885CYP4A11 2827/4885GSK3B 4365/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | CYP4F2 3413/4885CYP4A11 3227/4885GSK3B 3806/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | CYP4F2 4694/4885CYP4A11 4346/4885GSK3B 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.